Carmeseal-MD to enter clinical trial

 

Phrixus Pharmaceuticals has announced that they now have the funding to go ahead with a small clinical trial of Carmeseal-MD for Duchenne. Save Our Sons committed US$25,000 to this project.

Carmeseal-MD (also known as poloxamer 188) is a polymer that shows promise as a treatment for Duchenne due to its ability to stabilise muscle cell membranes. In particular, it is hoped that it will help with heart and lung function.

The trial will be run at Cincinnati Children's Hospital and will involve around eight non-ambulatory boys and young men. We are excited that treatment and clinical trial options are coming forward for this older age group.

Read the press release.

Q and As available for more information. 

More information on the Save Our Sons website.

Posted 10/25/2017